Mixed β 3-adrenoceptor agonist and α 1- adrenoceptor antagonist properties of nebivolol in rat thoracic aorta

British Journal of Pharmacology

Volumn 147, Issue 7, 2006, Pages 699-706

  Rozec, Bertrand ^a,b,d   Thuy, Tran Quang ^a   Noireaud, Jacques ^a   Gauthier, Chantal ^a,c  

^a L INSTITUT DU THORAX   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

1 adrenoceptor; 3 adrenoceptor; Nebivolol; NO; Rat aorta; Vasodilatation

Indexed keywords

[[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; [N [4 [2 [[3 [3 (ACETAMIDOMETHYL)PHENOXY] 2 HYDROXYPROPYL]AMINO]ETHYL] PHENYL]BENZENESULFONAMIDE]; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIN 1; L 748337; N(G) METHYLARGININE; NADOLOL; NEBIVOLOL; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BENZOPYRAN DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE; NITRIC OXIDE;

AGONIST; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG TARGETING; HEART FAILURE; HYPERTENSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SYMPATHETIC TONE; THORACIC AORTA; TREATMENT INDICATION; VASCULAR RING; VASODILATATION; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; MUSCLE CONTRACTION; MUSCLE RELAXATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA, THORACIC; BENZOPYRANS; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PHENYLEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-3; SIGNAL TRANSDUCTION;

EID: 33645551732     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706648     Document Type: Article

References (50)

1. ALTWEGG, L.A., D'USCIO, L.V., BARANDIER, C., COSENTINO, F., YANG, Z. & LUSCHER, T.F. (2000). Nebivolol induces NO-mediated relaxations of rat mesenteric but not large elastic arteries. J. Cardiovasc. Pharmacol., 36, 316-320.
2. ANDRE, D.E., ARNET, U., YANG, Z. & LUSCHER, T.F. (2000). Nebivolol inhibits human aortic smooth muscle cell growth: effects of cell cycle regulatory proteins. J. Cardiovasc. Pharmacol., 35, 845-848.
3. ARCH, J.R. (2002). beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur. J. Pharmacol., 440, 99-107.
4. BOWMAN, A.J., CHEN, C.P. & FORD, G.A. (1994). Nitric oxide mediated venodilator effects of nebivolol. Br. J. Clin. Pharmacol., 38, 199-204.
5. BRAHMADEVARA, N., SHAW, A.M. & MACDONALD, A. (2003). Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta. Br. J. Pharmacol., 138, 99-106.
6. BRAHMADEVARA, N., SHAW, A.M. & MACDONALD, A. (2004). Alpha1-adrenoceptor antagonist properties of CGP 12177A and other beta-adrenoceptor ligands: evidence against beta(3)- or atypical beta-adrenoceptors in rat aorta. Br. J. Pharmacol., 142, 781-787.
7. BREHM, B.R., WOLF, S.C., BERTSCH, D., KLAUSSNER, M., WESSELBORG, S. & SCHULZE-OSTHOFF, K. (2001). Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc. Res., 49, 430-439.
8. BROEDERS, M.A., DOEVENDANS, P.A., BEKKERS, B.C., BRONSAER, R., VAN GORSEL, E., HEEMSKERK, J.W., EGBRINK, M.G., VAN BREDA, E., RENEMAN, R.S. & VAN DER ZEE, R. (2000). Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation, 102, 677-684.
9. CANDELORE, M.R., DENG, L., TOTA, L., GUAN, X.M., AMEND, A., LIU, Y., NEWBOLD, R., CASCIERI, M.A. & WEBER, A.E. (1999). Potent and selective human beta(3)-adrenergic receptor antagonists. J. Pharmacol. Exp. Ther., 290, 649-655.
10. CARPENE, C., CASTAN, I., COLLON, P., GALITZKY, J., MORATINOS, J. & LAFONTAN, M. (1994). Adrenergic lipolysis in guinea pig is not a beta 3-adrenergic response: comparison with human adipocytes. Am. J. Physiol., 266, R905-R913.
11. 1A -receptors. J. Physiol. Pharmacol., 53, 615-624.
12. COCKCROFT, J.R., CHOWIENCZYK, P.J., BRETT, S.E., CHEN, C.P., DUPONT, A.G., VAN NUETEN, L., WOODING, S.J. & RITTER, J.M. (1995). Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther., 274, 1067-1071.
13. COSENTINO, F., BONETTI, S., REHORIK, R., ETO, M., WERNER-FELMAYER, G., VOLPE, M. & LUSCHER, T.F. (2002). Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1-selective receptor blockade. J. Hypertens., 20, 421-428.
14. DE GROOT, A.A., MATHY, M.J., VAN ZWIETEN, P.A. & PETERS, S.L. (2003). Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J. Cardiovasc. Pharmacol., 42, 232-236.
15. DESSY, C., MONIOTTE, S., GHISDAL, P., HAVAUX, X., NOIRHOMME, P. & BALLIGAND, J.L. (2004). Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation, 110, 948-954.
16. 3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third generation β-blocker nebivolol. Circulation, 112, 1198-1205.
17. DONCKIER, J.E., MASSART, P.E., VAN MECHELEN, H., HEYNDRICKX, G.R., GAUTHIER, C. & BALLIGAND, J.L. (2001). Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur. J. Clin. Invest., 31, 681-689.
18. FLATHER, M.D., SHIBATA, M.C., COATS, A.J., VAN VELDHUISEN, D.J., PARKHOMENKO, A., BORBOLA, J., COHEN-SOLAL, A., DUMITRASCU, D., FERRARI, R., LECHAT, P., SOLER-SOLER, J., TAVAZZI, L., SPINAROVA, L., TOMAN, J., BOHM, M., ANKER, S.D., THOMPSON, S.G., POOLE-WILSON, P.A. & Seniors Investigators. (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J., 26, 215-225.
19. FRATTA PASINI, A., GARBIN, U., NAVA, M.C., STRANIERI, C., DAVOLI, A., SAWAMURA, T., LO CASCIO, V. & COMINACINI, L. (2005). Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens., 23, 589-596.
20. GAO, Y.S., NAGAO, T., BOND, R.A., JANSSENS, W.J. & VANHOUTTE, P.M. (1991). Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol., 17, 964-969.
21. GAUTHIER, C., TAVERNIER, G., TROCHU, J.N., LEBLAIS, V., LAURENT, K., LANGIN, D., ESCANDE, D. & LE MAREC, H. (1999). Interspecies differences in the cardiac negative inotropic effects of beta(3)-adrenoceptor agonists. J. Pharmacol. Exp. Ther., 290, 687-693.
22. GEORGESCU, A., PLUTEANU, F., FLONTA, M.L., BADILA, E., DOROBANTU, M. & POPOV, D. (2005). The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur. J. Pharmacol., 508, 159-166.
23. GOSGNACH, W., BOIXEL, C., NEVO, N., POIRAUD, T. & MICHEL, J.B. (2001). Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway. J. Cardiovasc. Pharmacol., 38, 191-199.
24. GRANNEMAN, J.G. & LAHNERS, K.N. (1994). Analysis of human and rodent beta 3-adrenergic receptor messenger ribonucleic acids. Endocrinology, 135, 1025-1031.
25. HUSSAIN, M.B. & MARSHALL, I. (1997). Characterization of alpha1-adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. Br. J. Pharmacol., 122, 849-858.
26. HUTCHINSON, D.S., SATO, M., EVANS, B.A., CHRISTOPOULOS, A. & SUMMERS, R.J. (2005). Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1- ylamino]-2S-2-propanol oxalate]. J. Pharmacol. Exp. Ther., 312, 1064-1074.
27. IGNARRO, L.J. (2004). Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third generation beta-blocker. Blood Press., 1, 2-16.
28. IGNARRO, L.J., BYRNS, R.E., TRINH, K., SISODIA, M. & BUGA, G.M. (2002). Nebivolol: a selective β(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide, 7, 75-82.
29. KAKOKI, M., HIRATA, Y., HAYAKAWA, H., NISHIMATSU, H., SUZUKI, Y., NAGATA, D., SUZUKI, F., KIKUCHI, K., NAGANO, T. & OMATA, M. (1999). Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension, 33, 467-471.
30. KALINOWSKI, L., DOBRUCKI, L.W., SZCZEPANSKA-KONKEL, M., JANKOWSKI, M., MARTYNIEC, L., ANGIELSKI, S. & MALINSKI, T. (2003). Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive actions. Circulation, 107, 2747-2752.
31. LOOTS, W. & DE CLERCK, F. (1990). Differential effects of nebivolol on adrenoceptors in the heart and in resistance arterioles in the rat. Quantitative intravital microscopic analysis. Eur. J. Pharmacol., 179, 177-186.
32. LOUIS, A., CLELAND, J.G., CRABBE, S., FORD, S., THACKRAY, S., HOUGHTON, T. & CLARK, A. (2001). Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology. Eur. J. Heart. Fail, 3, 381-387.
33. MALLEM, M.Y., TOUMANIANTZ, G., SERPILLON, S., GAUTIER, F., GOGNY, M., DESFONTIS, J.C. & GAUTHIER, C. (2004). Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br. J. Pharmacol., 143, 599-605.
34. MANGRELLA, M., FICI, F. & ROSSI, F. (1998). Pharmacology of nebivolol. Pharmacol. Res., 38, 419-431.
35. NODARI, S., METRA, M. & DEI CAS, L. (2003). β-Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs Nebivolol. Eur. J. Heart Failure, 5, 621-627.
36. PARENTI, A., FILIPPI, S., AMERINI, S., GRANGER, H.J., FAZZINI, A. & LEDDA, F. (2000). Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol. J. Pharmacol. Exp. Ther., 292, 698-703.
37. PAUWELS, P.J., GOMMEREN, W., VAN LOMMEN, G., JANSSEN, P.A. & LEYSEN, J.E. (1988). The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol. Pharmacol., 34, 843-851.
38. 3-Adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br. J. Pharmacol., 137, 153-161.
39. RITTER, J.M. (2001). Nebivolol: endothelium-mediated vasodilating effect. J. Cardiovasc. Pharmacol., 38, S13-S16.
40. ROZEC, B., SERPILLON, S., TOUMANIANTZ, G., SEZE, C., RAUTUREAU, Y., BARON, O., NOIREAUD, J. & GAUTHIER, C. (2005). Characterization of beta3-adrenoceptors in human internal mammary artery and putative involvement in coronary artery bypass management. J. Am. Coll. Cardiol., 46, 351-359.
41. SCHEEN, A.J. (2001). Pharma-clinics medication of the month, Nebivolol (Nobiten). Rev. Med. Liege, 56, 788-791.
42. SCHNEIDER, J., FRUH, C., WILFFERT, B. & PETERS, T. (1990). Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat. Pharmacology, 40, 33-41.
43. SHEN, Y.T., CERVONI, P., CLAUS, T. & VATNER, S.F. (1996). Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J. Pharmacol. Exp. Ther., 278, 1435-1443.
44. SHIMIZU, K. & MC GRATH, BP. (1993). Sympathetic dysfunction in heart failure. Bailleres Clin. Endocrinol. Metab., 7, 439-463.
45. TAVERNIER, G., GALITZKY, J., BOUSQUET-MELOU, A., MONTASTRUC, J.L. & BERLAN, M. (1992). The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J. Pharmacol. Exp. Ther., 263, 1083-1090.
46. TODA, N. (2003). Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol. Ther., 100, 215-234.
47. TROCHU, J.N., LEBLAIS, V., RAUTUREAU, Y., BÉVÉRELLI, F., LE MAREC, H., BERDEAUX, A. & GAUTHIER, C. (1999). Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br. J. Pharmacol., 128, 69-76.
48. VAN BORTEL, L.M., DE HOON, J.N., KOOL, M.J., WIJNEN, J.A., VERTOMMEN, C.I. & VAN NUETEN, L.G. (1997). Pharmacological properties of nebivolol in man. Eur. J. Clin. Pharmacol., 51, 379-384.
49. WAEBER, B. (2000). Nebivolol: a beta blocker with vasodilator properties. Schweiz Rundsch. Med. Prax., 89, 631-633.
50. ZANCHETTI, A. (2004). Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press, 1, 17-32.